Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Great RNS
Should be plenty more in the pipeline ready to drop.
Looking forward to the submarine surfacing and the confirmation of CTA for 1801 and its chosen indication
Sar is worth billions - just waiting for the world to catch up
GLA
Hi All
The rules around submarine patents are clear. The company can lodge a patent before it has completed its full work that would create an invention it wishes to patent (stay under water - hidden). This is to prevent ‘competition’ getting ahead and filing a patent for the same/similar invention. The general rule is the inventor has 18 months until the information has to be disclosed (surface).
John clearly found something they thought was worth protecting (dive dive dive). Shouldn’t be much longer for us to find out.
When we pushed him at the time we discovered the patent had been filed, he claimed they needed confidentiality and that “The world will find out soon.......” All this after the BoD claimed no more discoveries or new drugs a few months before and in the midst of a global pandemic.......
GLA
Hi All
Another covid ‘pill’ showing promising efficacy. Interesting that this is a kinase selective inhibitor.
RedHill is an Israeli based biopharma.
https://www.redhillbio.com/our-programs/pipeline/opaganib/covid-19/default.aspx
Opaganib, a first-in-class new chemical entity, is a sphingosine kinase-2 (SK2) selective inhibitor in oral pill form, with dual anti-inflammatory and antiviral activity. Opaganib’s unique mechanism is host-targeted and therefore expected to be effective against emerging viral variants.
Come on SAR you need to be joining the party with our ‘superior to dexamethasone’ and similar to baricitinib SDC-1801, the world needs more therapeutics.
GLA
Hi All
I would tend to agree with Potnak regarding our SDC-1801, however in comms from SAR in late 2020 I’m sure JR referred to the antiviral relationship.
Scientists and researchers have now been working on understanding covid for the last 18 mths and knowledge is gaining all the time. The most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, and hyperferritinemia, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion.
In severe cases, this leads to sepsis, blood clots, and multiple organ failure, including hypoxic and inflammatory damage to various vital organs, such as the brain, heart, liver, pancreas, kidneys, and intestines.
That said, in patients who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments (current standard of care) are intubation, injected corticosteroids (dexamethasone), and blood thinners. This however is not considered the correct treatment for COVID-19 and alternatives are being trialled. In severe hypoxia, cellular metabolic shifts cause hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue. This is called ischemia-reperfusion injury, and it’s why the majority of people who go on a ventilator are dying. In the mitochondria, succinate buildup due to sepsis does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals.
The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress. This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes. Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes (aka cytokine storm). This is similar to the pathophysiology of Lupus and this has been previously linked to our SDC-1801 by SRI, indeed these experiments by SRI led to the selection of SDC-1801 (formerly SAR-20351).
From the above, it is clear, how and where in the process our SDC-1801 could be used as an intervention for diagnosed and severely effected covid patients.
We will be in the mix somewhere but timing and next steps is still not clear.
GLA
Hi All
Based on the Aug update from TM, I predict (IMHO) that the CTA will need to announced by w/c 18 October. This is based on the timing to approval of our last CHK1 CTA in 2016 before the on license to Sierra. That went like this:
CTA - 01 Feb 2016
Approval - 06 April 2016
Trials open - 23 May 2016
TM stated the CTA for SDC-1801 will be made in Q4 with trials in early Q1. So working back from say last working day in December to grant approval to commence in early Q1 2022 will mean we should here any day from now upto 18 Oct (or they will be running late - will the HNWI’s let them slide on timing - I think not)
Add to this two news announcements due on patents (submarine and SDC-1802 ‘associated’), plus financial year end and AGM then Q4 will be an abundance of news flow. Furthermore, based on recent ‘silence’ from Sareum then we should be in for transformational news........finally, not even mentioned SRA737 and our covid angle.
GLA
Hi All - IMHO the announcement of the chosen indication for SDC-1801 will be the most significant news in SAR’s history as it will set the final roadmap for business. I’m excited by this and looking forward to it so much. It’s been an incredible journey to see our development.
The CTA is literally ‘round the corner’ and is the reason our HNWI’s joined the party. The clinical trial plans will be in the final stages with trial locations and hospitals being selected.
GLA
Hi Afham
All we can do is speculate on what is happening or about to happen. That said, the facts of what we know are about to happen in the coming Q4 are enough to keep me sat firmly on my hands. We have:
SDC-1802 ‘associated’ patent
The submarine patent
CTA for SDC-1801
Announcing of the indication for SDC-1801 CTA
SAR Financial Year end approaching with updates
AGM with more release of updates
Going to be a great end to the year and this is without consideration of the wide speculation we have regards large pharma interest in our TYK2s, the covid/bacterial pneumonia angle, UK/WHO covid trials, take overs & buyouts, license deals and finally SRA737 news!
Hold for gold folks
Great synopsis SOG
You are correct with the original SDC-1802 sub patent, it was considered too similar by the examiner to our existing patents for TYK2s. John appealed and eventually won. That was the Jan 2020 award. Now the new SDC-1802 patent ‘notice of allowance’ for an ‘association’ is very intriguing - this could be as mentioned another molecule or indication which maybe the bacterial pneumonia angle (covid).
We then of course have the submarine patent which was described as crystalline formulation......everything lining up nicely
GLA
Hi All - extract from the trial results:
There was no significant difference in the occurrence of serious adverse events between treatment groups (remdesivir, 135 [33%] of 406 vs control, 130 [31%] of 418; p=0·48). Three deaths (acute respiratory distress syndrome, bacterial infection, and hepatorenal syndrome) were considered related to remdesivir by the investigators, but only one by the sponsor's safety team (hepatorenal syndrome).
No clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support.
It’s amazing how much the world has spent on a ‘clear dud’
Bring on SDC-1801 - superior to dexamethasone
GLA
Great sentiment WiP
It has been a very long road, but like you, I feel we are closer than ever. We have been told we are on track for trials in early 2022 and CTA in Q4. Tim will not let these slip further now that we have cash on hand from the HNWI’s.
I’m filled with nervous excitement regarding the indication we will target with trials and this news is not too far off now. Will they play safe with an already treated condition or go all out on unmet need?????
There are many news events due which we have all listed previously, any of which could drop anytime.
Keep the faith All and sit on your hands.
Hi Cozz
No this is not related to Sareum. The trial is for a test that can detect cancers by finding bio markers in a person’s blood. All tumors give off cell free DNA (cDNA) that can be detected in the blood.
It’s basically an early warning or scanning test that can help diagnose cancer. As with all cancers, the earlier it’s detected the better.
ATB
Hi All
Just as a continuation from Bobbler, and another thought:
We are due to submit a clinical trials application for our first in human trials for SDC-1801 (in Q4 as per latest RNS), what remains to be determined is the indication we will target - what if this turns out to be sepsis!! What if the HNWI’s have invested to see our Tyk2 progress into this unmet global need (with the potential links to the Gates Foundation/Wellcome)
Krone’s tweet from Sareum in 2020 could well be clue we have overlooked and everything has been leading this way since. Certainly an interesting thought!
GLA
Just for those recent investors who would not necessarily know about our SKIL
Sareum’s SKIL® (Sareum Kinase Inhibitor Library) discovery platform is based on a chemical template which can be adapted to inhibit many different kinases. SKIL compounds demonstrate high potency with good selectivity. Lead compounds have been developed that are suitable for i.v. or oral administration.
The intellectual property surrounding the SKIL chemical template, specific examples and their uses is protected by granted and pending patents.
The SKIL platform has generated compounds for Sareum's Aurora+FLT3, ALK and VEGFR-3 kinase cancer programmes and its TYK2 and FLT3 auto-immune disease programmes.
We routinely screen SKIL compounds to discover leads against new kinase targets. Due to our strong IP position, these leads have very low exposure to competitors' "submarine" patents (patents that have been filed but not yet published).
The IP value of the SKIL platform is in its own worth a substantial amount, even more so should our upcoming planned first in human trials prove successful.
Hi All
We know that our SKIL had been the vehicle that made our drug discoveries and have often debated on the value of such a ‘library’ should we be taken over or bought out. Below is an indication!
https://endpts.com/boehringer-ingelheim-taps-a-popular-antibody-discovery-player-for-access-to-drug-library-of-libraries/
GLA
Yes good digging Thoth
The same article was on Endpoints also, I must admit I didn’t join the dots initially.
‘We are honoured’ - speaks volumes
https://endpts.com/covid-19-roundup-gates-foundation-exscientia-team-up-on-pandemic-antiviral-discovery-pact-novavax-opens-trial-for-coronavirus-flu-combo-vaccine/
ATB
Hi All - this is likely our ‘sweet spot’ with SDC-1802 which has been developed to treat T-ALL cancers
New cancer-fighting discovery identifies patients who respond better to T cell immunotherapy
https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fnews.sky.com%2Fstory%2Fnew-cancer-fighting-discovery-identifies-patients-who-respond-better-to-t-cell-immunotherapy-12403121&data=04%7C01%7C%7C9eaf9534f771432cbba608d974366ace%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637668599326820211%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=DOxTkJXcq5PpIwywkzyDcMUyy3HHZKtjpX1eK1H%2BHQA%3D&reserved=0
GLA
Hi Citizen
Great post and equally interesting video of the 5 specialists dealing on a daily basis with prescribing kinase inhibitors for RA. My takeaway is that they will continue to prescribe despite the FDA advice as they feel patients dealing with RA would rather take the risk on cardiovascular issues than suffer the debilitating pain of RA, caveated by so long as the patient is fully aware of the side effects risks. The doctors were looking for ‘guilt free’ prescribing.
Time for cleaner more selective kinase inhibitors like our 2nd generation SDC’s. I’m 100% sure the likes of the specialists in the video would be fully supportive, who knows they may even be involved in future trials for our candidates.
GLA